Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) CMO David Shapiro sold 411 shares of the firm’s stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $153.34, for a total transaction of $63,022.74. Following the completion of the sale, the chief marketing officer now owns 44,272 shares of the company’s stock, valued at approximately $6,788,668.48. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

David Shapiro also recently made the following trade(s):

  • On Monday, October 3rd, David Shapiro sold 1,513 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $163.08, for a total transaction of $246,740.04.
  • On Monday, September 26th, David Shapiro sold 3,545 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $165.08, for a total transaction of $585,208.60.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) traded down 4.67% during mid-day trading on Wednesday, reaching $144.75. 477,345 shares of the company’s stock traded hands. The stock’s market capitalization is $3.58 billion. The stock’s 50 day moving average is $156.21 and its 200-day moving average is $151.20. Intercept Pharmaceuticals Inc. has a 52 week low of $89.76 and a 52 week high of $217.99.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.69) by $0.55. The business had revenue of $5.52 million for the quarter, compared to analyst estimates of $1.72 million. Intercept Pharmaceuticals had a negative net margin of 5,003.95% and a negative return on equity of 50.58%. The company’s revenue for the quarter was up 1140.4% compared to the same quarter last year. During the same period last year, the firm posted ($1.99) earnings per share. On average, equities analysts anticipate that Intercept Pharmaceuticals Inc. will post ($16.31) EPS for the current year.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Several equities research analysts have recently issued reports on ICPT shares. Robert W. Baird restated an “outperform” rating and issued a $332.00 target price on shares of Intercept Pharmaceuticals in a report on Wednesday, June 15th. Wedbush restated an “outperform” rating and issued a $239.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, June 24th. Cantor Fitzgerald started coverage on shares of Intercept Pharmaceuticals in a report on Wednesday, July 6th. They issued a “sell” rating and a $58.00 target price for the company. Laidlaw lowered shares of Intercept Pharmaceuticals from a “buy” rating to a “sell” rating and lowered their target price for the stock from $345.00 to $105.00 in a report on Friday, August 5th. Finally, Credit Suisse Group AG reiterated a “buy” rating and set a $200.00 price objective on shares of Intercept Pharmaceuticals in a report on Friday, August 5th. Five research analysts have rated the stock with a sell rating, five have issued a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $177.67.

Several institutional investors have recently made changes to their positions in ICPT. Aperio Group LLC raised its position in shares of Intercept Pharmaceuticals by 31.2% in the first quarter. Aperio Group LLC now owns 2,152 shares of the biopharmaceutical company’s stock worth $276,000 after buying an additional 512 shares during the period. BlackRock Inc. raised its position in shares of Intercept Pharmaceuticals by 301.5% in the first quarter. BlackRock Inc. now owns 1,915 shares of the biopharmaceutical company’s stock worth $246,000 after buying an additional 1,438 shares during the period. BlackRock Group LTD raised its position in shares of Intercept Pharmaceuticals by 20.1% in the first quarter. BlackRock Group LTD now owns 13,074 shares of the biopharmaceutical company’s stock worth $1,680,000 after buying an additional 2,188 shares during the period. BlackRock Fund Advisors raised its position in shares of Intercept Pharmaceuticals by 7.2% in the first quarter. BlackRock Fund Advisors now owns 467,272 shares of the biopharmaceutical company’s stock worth $60,030,000 after buying an additional 31,289 shares during the period. Finally, State Street Corp raised its position in shares of Intercept Pharmaceuticals by 27.5% in the first quarter. State Street Corp now owns 521,407 shares of the biopharmaceutical company’s stock worth $66,990,000 after buying an additional 112,431 shares during the period. Institutional investors and hedge funds own 81.86% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.